in anuric patients receiving continuous venovenous hemofiltration [2] . The clinical relevance of these inactive metabolites is essentially unknown. Moreover, because prolonged use of linezolid might be associated with severe hematopoietic and neurologic adverse effects, special attention has to be paid to the potential toxicity associated with linezolid accumulation.
Adjustment of Antimicrobial Dosages for Continuous Venovenous Hemofiltration Based on Patient-Specific Information
Sir-We applaud the efforts of Trotman et al. [1] to bring the pharmacokinetic tailoring of treatment with anti-infective agents in continuous renal replacement therapy to the forefront of infectious diseases clinical practice; however, we feel that the tables presented in their article [1] may represent an oversimplified dosing algorithm. 6 ]. Drug clearance must be calculated to determine a maintenance dose. The serum concentration at steady state (Cp ss , measured in mg/L) multiplied by the extracorporeal clearance rate (measured in L/ h) provides the practitioner with the amount of drug specifically removed by ultrafiltration per hour under steady-state conditions [7] . This allows for calculation of varying maintenance dosages based on the ultrafiltration rate and duration. One can calculate the amount of drug removed by CVVH with the extracorporeal unit (D extr ) with the equation D extr p (Cp ss ϫ Sc ϫ UFR) ϫ duration of CVVH, where the duration of CVVH is measured in hours. Because the total drug clearance in an anephric individual is equal to the anuric clearance plus the extracorporeal clearance [6] , the amount of drug that must be replaced includes the typical anephric dose (D anuric ) in addition to the amount removed by ultrafiltration: D p D extr + D anuric .
These calculations represent estimates of true drug clearance during CVVH. Continuous venovenous hemodialysis, a diffusive and more complex process, is subject to saturation [6] . Therefore, use of the above equations may result in dosages higher than what is necessary to replace extracorporeal losses. Pharmacokinetics are often less predictable in critically ill patients; there can be substantial intraindividual and interindividual variation. When possible, antibiotic concentrations in serum should be measured to guide dosage adjustment [4] . As Trotman et al. [1] point out, clinical data will be needed to support additional efforts, and these calculations are meant to support rather than supersede clinical judgment. Finally, studies with directly generalizable results should take precedence over a single calculation.
